Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy
The prognostic significance of a response to highly active antiretroviral therapy (HAART) that is immunologically and virologically discordant is not well understood. Four hundred four antiretroviral-naive patients initiating HAART at an urban HIV outpatient clinic in 1995 to 2004 were analyzed. The...
Saved in:
Published in | Journal of acquired immune deficiency syndromes (1999) Vol. 47; no. 5; p. 553 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
15.04.2008
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | The prognostic significance of a response to highly active antiretroviral therapy (HAART) that is immunologically and virologically discordant is not well understood.
Four hundred four antiretroviral-naive patients initiating HAART at an urban HIV outpatient clinic in 1995 to 2004 were analyzed. The association of treatment responses at 3 to 9 months after HAART initiation with time to development of an opportunistic infection (OI) or death was determined using Cox proportional hazards modeling. Logistic regression modeling was used to examine the association between discordant responses and patient characteristics.
Of 404 patients, 70.5% experienced favorable concordant responses (CD4 cell count [CD4]+/viral load [VL]+: increase in CD4 count of >or=50 cells/microL and achievement of undetectable plasma HIV RNA level), 15.8% an immunologic response only (CD4+/VL(-)), 8.7% a virologic response only (CD4(-)/VL+), and 5.0% a concordant unfavorable response (CD4(-)/VL(-)). Both types of discordant responses (CD4+/VL(-) and CD4(-)/VL+), nonresponse (CD4(-)/VL(-)), and baseline CD4 cell count were significantly associated with earlier development of an OI or death (relative hazard [RH] = 2.81, 95% confidence interval [CI]: 1.31 to 3.97; RH = 4.83, 95% CI: 2.10 to 11.12; and RH = 0.93, 95% CI: 0.88 to 0.99, respectively). CD4+/VL(-) and CD4(-)/VL(-) were associated with nonwhite race in multivariate logistic regression models (adjusted OR = 2.83, 95% CI: 1.46 to 5.47 and adjusted OR = 6.50, 95% CI: 1.65 to 25.69, respectively).
Discordant immunologic and virologic responses at 3 to 9 months after HAART initiation play important roles in predicting long-term clinical outcomes in treatment-naive patients. |
---|---|
AbstractList | The prognostic significance of a response to highly active antiretroviral therapy (HAART) that is immunologically and virologically discordant is not well understood.
Four hundred four antiretroviral-naive patients initiating HAART at an urban HIV outpatient clinic in 1995 to 2004 were analyzed. The association of treatment responses at 3 to 9 months after HAART initiation with time to development of an opportunistic infection (OI) or death was determined using Cox proportional hazards modeling. Logistic regression modeling was used to examine the association between discordant responses and patient characteristics.
Of 404 patients, 70.5% experienced favorable concordant responses (CD4 cell count [CD4]+/viral load [VL]+: increase in CD4 count of >or=50 cells/microL and achievement of undetectable plasma HIV RNA level), 15.8% an immunologic response only (CD4+/VL(-)), 8.7% a virologic response only (CD4(-)/VL+), and 5.0% a concordant unfavorable response (CD4(-)/VL(-)). Both types of discordant responses (CD4+/VL(-) and CD4(-)/VL+), nonresponse (CD4(-)/VL(-)), and baseline CD4 cell count were significantly associated with earlier development of an OI or death (relative hazard [RH] = 2.81, 95% confidence interval [CI]: 1.31 to 3.97; RH = 4.83, 95% CI: 2.10 to 11.12; and RH = 0.93, 95% CI: 0.88 to 0.99, respectively). CD4+/VL(-) and CD4(-)/VL(-) were associated with nonwhite race in multivariate logistic regression models (adjusted OR = 2.83, 95% CI: 1.46 to 5.47 and adjusted OR = 6.50, 95% CI: 1.65 to 25.69, respectively).
Discordant immunologic and virologic responses at 3 to 9 months after HAART initiation play important roles in predicting long-term clinical outcomes in treatment-naive patients. |
Author | Tan, Ruimin Saag, Michael S Kaslow, Richard A Westfall, Andrew O Kempf, Mirjam C Willig, James H Mugavero, Michael J |
Author_xml | – sequence: 1 givenname: Ruimin surname: Tan fullname: Tan, Ruimin organization: Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL 35294-0022, USA – sequence: 2 givenname: Andrew O surname: Westfall fullname: Westfall, Andrew O – sequence: 3 givenname: James H surname: Willig fullname: Willig, James H – sequence: 4 givenname: Michael J surname: Mugavero fullname: Mugavero, Michael J – sequence: 5 givenname: Michael S surname: Saag fullname: Saag, Michael S – sequence: 6 givenname: Richard A surname: Kaslow fullname: Kaslow, Richard A – sequence: 7 givenname: Mirjam C surname: Kempf fullname: Kempf, Mirjam C |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/18285713$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkMFKAzEYhHOo2Fp9A5G8wNZkk-xmj6WoLRREUK8lTf50I7vJkqSVvopPa8V68DQMzDcDc4VGPnhA6JaSGSVNff8yX83IllAGjEpaSVFpMUITKkpRcMrEGF2l9EEIrThvLtGYylKKmrIJ-lp0zjutOhz2WYcecLB4uXovnLegMxisfHYRcgwHF1VXeOUOgAeVHfic8KfLLTYu6RDNKYld3-996MLO6RNp8Ak6uwhpCD5Bwjng1u3a7oiVzj9t_ydwbiGq4XiNLqzqEtycdYreHh9eF8ti_fy0WszXheaMi6IyrJIKpLaMWspqaaS1rJGSat4IAFYRLTnUVirLRWm1UUxR2eiGczAEyim6--0d9tsezGaIrlfxuPk7qfwGwthwIg |
CitedBy_id | crossref_primary_10_1071_SH09120 crossref_primary_10_1016_j_jmii_2023_06_005 crossref_primary_10_1586_1744666X_2013_842897 crossref_primary_10_1089_aid_2020_0270 crossref_primary_10_2217_hiv_10_36 crossref_primary_10_1002_jmv_27696 crossref_primary_10_1097_QAD_0b013e32834f32f8 crossref_primary_10_1016_j_eimc_2010_03_002 crossref_primary_10_52420_2071_5943_2022_21_5_67_73 crossref_primary_10_1182_blood_2010_12_322453 crossref_primary_10_1111_imr_12064 crossref_primary_10_4236_ojmm_2024_142008 crossref_primary_10_1371_journal_pone_0087160 crossref_primary_10_1016_j_imlet_2017_08_014 crossref_primary_10_1016_j_jiac_2016_09_003 crossref_primary_10_1016_j_bjid_2018_09_002 crossref_primary_10_1590_S0036_46652011000600001 crossref_primary_10_1016_j_clim_2013_12_005 crossref_primary_10_1177_0956462413496771 crossref_primary_10_1371_journal_pone_0115125 crossref_primary_10_1097_QAI_0000000000001021 crossref_primary_10_1002_JLB_4MR1019_189R crossref_primary_10_1093_aje_kwq101 crossref_primary_10_1371_journal_ppat_1009825 crossref_primary_10_1097_QAD_0000000000000805 crossref_primary_10_3389_fimmu_2019_00025 crossref_primary_10_1371_journal_pone_0015663 crossref_primary_10_1371_journal_pone_0124741 crossref_primary_10_7448_IAS_17_1_18651 crossref_primary_10_1016_j_cyto_2013_01_003 crossref_primary_10_1093_jinfdis_jiq055 crossref_primary_10_2174_1874613601913010025 crossref_primary_10_1097_QAI_0000000000000892 crossref_primary_10_1097_QAI_0b013e3181ec28ff crossref_primary_10_1134_S1990519X19010097 crossref_primary_10_1097_QAD_0b013e328361a3fe crossref_primary_10_1097_QAI_0b013e3181c22d19 crossref_primary_10_1097_QAI_0b013e31820fffba crossref_primary_10_1186_s12967_015_0601_2 crossref_primary_10_1016_j_medmal_2015_03_009 crossref_primary_10_1007_s13337_011_0045_0 crossref_primary_10_1080_21505594_2016_1216293 crossref_primary_10_1089_aid_2020_0254 crossref_primary_10_1371_journal_pone_0132430 crossref_primary_10_22328_2077_9828_2019_11_1_16_30 crossref_primary_10_1080_09540121_2021_1929813 crossref_primary_10_1371_journal_pone_0105853 crossref_primary_10_1086_595851 crossref_primary_10_1371_journal_pone_0061264 crossref_primary_10_1186_1479_5876_10_94 crossref_primary_10_1186_s12879_021_06260_y crossref_primary_10_1089_aid_2014_0038 crossref_primary_10_1186_1471_2334_11_306 crossref_primary_10_1371_journal_pone_0017956 crossref_primary_10_1186_1742_6405_7_14 crossref_primary_10_1089_aid_2012_0266 crossref_primary_10_1086_695852 crossref_primary_10_1097_QAD_0b013e32832f3c65 crossref_primary_10_1016_j_eimc_2008_11_002 crossref_primary_10_1016_j_ijid_2019_01_017 crossref_primary_10_1186_1471_2334_13_113 crossref_primary_10_7883_yoken_JJID_2018_105 crossref_primary_10_1097_QAI_0b013e3181b98537 crossref_primary_10_22328_2077_9828_2023_15_2_7_18 crossref_primary_10_1089_aid_2010_0230 crossref_primary_10_1097_QAI_0b013e3182219113 crossref_primary_10_1371_journal_pone_0156099 crossref_primary_10_1093_cid_cit921 crossref_primary_10_1096_fj_201500059 crossref_primary_10_1097_QAI_0b013e3181b62933 crossref_primary_10_2217_hiv_09_58 crossref_primary_10_3109_10408363_2013_865702 crossref_primary_10_1016_j_meegid_2016_03_037 crossref_primary_10_1111_j_1468_1293_2009_00821_x crossref_primary_10_1371_journal_pone_0159446 crossref_primary_10_1097_QAI_0b013e31819b15f3 crossref_primary_10_1016_j_jiph_2023_12_022 crossref_primary_10_1371_journal_pone_0080157 crossref_primary_10_1586_eri_11_106 crossref_primary_10_9778_cmajo_20200249 crossref_primary_10_2217_fvl_12_80 crossref_primary_10_3390_jcm11206077 crossref_primary_10_1097_QAD_0b013e32835cb747 crossref_primary_10_1007_s13365_013_0185_7 crossref_primary_10_1097_QAI_0000000000000398 crossref_primary_10_1371_journal_pone_0227124 crossref_primary_10_1016_j_ijid_2013_05_009 crossref_primary_10_1590_S0036_46652013000400008 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1097/QAI.0b013e31816856c5 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Medicine |
ExternalDocumentID | 18285713 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- .-D .XZ .Z2 01R 0R~ 1J1 354 40H 4Q1 4Q2 4Q3 53G 5GY 5RE 5VS 77Y 7O~ 8L- AAAAV AAAXR AAGIX AAHPQ AAIQE AAJCS AAMOA AARTV AASOK AAXQO ABBUW ABDIG ABIVO ABJNI ABXVJ ABZAD ACCJW ACDDN ACEWG ACGFO ACGFS ACILI ACOAL ACPRK ACWDW ACWRI ACXNZ ADGGA ADHPY ADNKB AE3 AE6 AEETU AFDTB AFEXH AFRAH AFUWQ AGINI AHMBA AHOMT AHQNM AHRYX AHVBC AIJEX AINUH AJIOK AJNWD AJNYG AJZMW ALMA_UNASSIGNED_HOLDINGS AMJPA AMNEI AWKKM BKOMP BOYCO BQLVK BYPQX C45 CGR CS3 CUY CVF DIWNM DUNZO E.X EBS ECM EIF EJD EX3 F2K F2L F2M F2N F5P FCALG FL- FRJ FRP FW0 H0~ HZ~ IKREB IKYAY IN~ JG8 JK3 JK8 K8S KD2 KMI L-C NPM N~7 N~B O9- OAG OAH OCUKA ODA ODMTH OHH OHYEH OLG OLH OLU OLV OLW OLY OLZ OPUJH ORVUJ OUVQU OVD OVDNE OVIDH OVLEI OWV OWX OWY OWZ OXXIT P2P PQQKQ RIG RLZ RXW S4R S4S TAE TEORI V2I VVN W2D W3M WOQ WOW X3V X3W XJT XYM YOC ZZMQN |
ID | FETCH-LOGICAL-c4345-6d368ae8cf31f1378d8ff39881c495ee360c84e7f8af452fcda3a189c944ed0e2 |
ISSN | 1525-4135 |
IngestDate | Sat Sep 28 07:44:53 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c4345-6d368ae8cf31f1378d8ff39881c495ee360c84e7f8af452fcda3a189c944ed0e2 |
OpenAccessLink | https://doi.org/10.1097/qai.0b013e31816856c5 |
PMID | 18285713 |
ParticipantIDs | pubmed_primary_18285713 |
PublicationCentury | 2000 |
PublicationDate | 2008-April-15 |
PublicationDateYYYYMMDD | 2008-04-15 |
PublicationDate_xml | – month: 04 year: 2008 text: 2008-April-15 day: 15 |
PublicationDecade | 2000 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Journal of acquired immune deficiency syndromes (1999) |
PublicationTitleAlternate | J Acquir Immune Defic Syndr |
PublicationYear | 2008 |
References | 19300103 - J Acquir Immune Defic Syndr. 2009 Apr 15;50(5):556-8 |
References_xml | |
SSID | ssj0016449 |
Score | 2.2972016 |
Snippet | The prognostic significance of a response to highly active antiretroviral therapy (HAART) that is immunologically and virologically discordant is not well... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 553 |
SubjectTerms | Adult Antiretroviral Therapy, Highly Active CD4 Lymphocyte Count Disease Progression Female HIV Infections - drug therapy HIV Infections - immunology HIV Infections - mortality HIV Infections - virology HIV-1 - drug effects Humans Logistic Models Male Middle Aged Multivariate Analysis Treatment Outcome Viral Load |
Title | Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy |
URI | https://www.ncbi.nlm.nih.gov/pubmed/18285713 |
Volume | 47 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtQwFLWmICE2iPcbecFuFBjHduIsqwrUIk0R0hR1V9mOXSGVSdVmkOBT-EV-gntje2Kmg3hsopk4sZPcE8e-955jQl7OjBB15UzBqhomKGXD4JVCN4cxbuY4yrMgG3l-WO0fiXfH8ngy-ZFlLa1688p-28or-R-rwj6wK7Jk_8Gy60phB_wG-8IWLAzbv7LxXqI1dqse6g9e-YOPRciwcqjC2kOX1qPb4EKfFUuNeUJRSjXy2pCWCxNQOHL6CbkioTMcYgpIgQv_LkImbZCDQIXjs6-DCscXt9HEtM9UCq6OebXFxGO4sKEppGyhgMXA_kzSCUE6CgaUmY9iEYNVK1yCbIwlXfZeh6hJSMucvv_Fi3S6zgIeGRjz1akGM3cZYyAGxpLnQ2EQJ3A_U2ddygI-wjLvzYN-Z0StzLpmGUSJr3wyghTxh92D0SfMKiUrK_PDwfDnnwcYMdT8qxn_c-mGkHcq2iE7tcJVRg7RsRQDXjAsbQZp33hLieXZ1K-3XRpq3cbqNuZDw7hocZvcisaluwGdd8jELe-SG_OYsnGPfE8gpRGktPM0ByndBlKaQEoRpHQEKc1ACme2dA1SugYp7TsaQEoDSDeaoBGk98nR2zeLvf0iLghSWMGFLKqWV0o7ZT1nnvFatcp73ijFLMzznePVzCrhaq-0F7L0ttVcM9XYRgjXzlz5gFxbdkv3iFDVWhidVqUBWAhemqYVzInSKdNIOFk9Jg_DUz05D6ovJ-l5P_ltyVNyc4TpM3Id3oFL9xzGrL15MVj7JyrXnXI |
link.rule.ids | 780 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+outcome+of+HIV-infected+antiretroviral-naive+patients+with+discordant+immunologic+and+virologic+responses+to+highly+active+antiretroviral+therapy&rft.jtitle=Journal+of+acquired+immune+deficiency+syndromes+%281999%29&rft.au=Tan%2C+Ruimin&rft.au=Westfall%2C+Andrew+O&rft.au=Willig%2C+James+H&rft.au=Mugavero%2C+Michael+J&rft.date=2008-04-15&rft.issn=1525-4135&rft.volume=47&rft.issue=5&rft.spage=553&rft_id=info:doi/10.1097%2FQAI.0b013e31816856c5&rft_id=info%3Apmid%2F18285713&rft_id=info%3Apmid%2F18285713&rft.externalDocID=18285713 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1525-4135&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1525-4135&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1525-4135&client=summon |